- Home
- VIVS vs RDHL Comparison
VIVS vs RDHL Comparison
Compare VIVS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | RDHL |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.0M |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VIVS | RDHL |
|---|---|---|
| Price | $0.28 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 619.2K | ★ 2.6M |
| Earning Date | 06-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,603,000.00 | N/A |
| Revenue This Year | $42.38 | $381.91 |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.82 | N/A |
| 52 Week Low | $0.26 | $0.57 |
| 52 Week High | $4.98 | $2.79 |
Technical Indicators
Market Signals| Indicator | VIVS | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 39.85 |
| Support Level | $0.27 | N/A |
| Resistance Level | $0.58 | $0.85 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 16.83 | 0.01 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.